Brief: Jw (Cayman) Therapeutics Posts IFRS Revenue Rmb145.7 Mln For Year
March 29 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* IFRS REVENUE RMB145.7 MILLION FOR YEAR, INCREASE OF 373.1%
* LOSS FOR YEAR WAS RMB846.1 MILLION VERSUS LOSS OF RMB702.3
MILLION
Source text for Eikon: ID:nHKSdvv6d
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License